What are the autoantibodies associated with Inclusion Body Myositis (IBM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The autoantibodies most commonly associated with inclusion body myositis (IBM) are anti-cN1A (anti-cytosolic 5'-nucleotidase 1A) antibodies, which are found in approximately 30-70% of IBM patients, as supported by the most recent study 1.

Key Findings

  • Anti-cN1A antibodies target the cN1A enzyme, which is involved in nucleotide metabolism, and their presence can help distinguish IBM from other inflammatory myopathies.
  • The presence of anti-cN1A antibodies has reasonable specificity for IBM, but they are not found in all patients, and can occasionally be detected in other conditions such as Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis.
  • Other less specific autoantibodies that may be present in some IBM patients include anti-nuclear antibodies (ANAs) and myositis-specific antibodies like anti-Jo-1, though these are more commonly associated with other inflammatory myopathies.

Clinical Implications

  • Testing for anti-cN1A antibodies can be a useful diagnostic tool when clinical presentation and muscle biopsy findings are inconclusive, but should be interpreted in the context of the overall clinical picture.
  • The presence of anti-cN1A antibodies supports the autoimmune component of IBM pathogenesis, though the disease also has degenerative features including protein aggregation similar to those seen in neurodegenerative disorders.
  • According to the study 1, anti-cN1A positivity had an overall sensitivity of 46.9% and a specificity of 93.2% for sIBM, and was associated with dysphagia in sIBM patients.

Diagnostic Considerations

  • The novel anti-cN1A IgG ELISA can improve and accelerate the diagnosis of sIBM using sera where muscle biopsy is delayed or unfeasible, as reported in the study 2.
  • The study 3 also found that combination assays of all 3 autoantibody levels (IgM, IgA, and IgG) improved diagnostic sensitivity to 76%.
  • However, it is essential to consider the limitations of anti-cN1A antibodies as a diagnostic tool, as they may not be present in all IBM patients, and can be detected in other conditions.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.